Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | TET3 | O43151 | 1/20 | 0.39 |
| ▸ | OTC | P00480 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3351368 | 1.00 | GPR84 (0.42) | GPR84FFAR1ALOX15MEN1KMT2A | |
| SCHEMBL28586986 | 1.00 | GPR84 (0.42) | GPR84FFAR1ALOX15MEN1KMT2A | |
| SCHEMBL3351322 | 0.94 | GPR84 (0.46) | GPR84FFAR1ALOX15MEN1KMT2A | |
| SCHEMBL25329849 | 0.93 | GPR84 (0.48) | GPR84FFAR1ALOX15MEN1KMT2A | |
| SCHEMBL3230889 | 0.88 | TET2 (0.41) | GPR84FFAR1ALOX15MEN1KMT2A | |
| SCHEMBL3347293 | 0.84 | GPR84 (0.45) | GPR84FFAR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3346616 | 0.84 | GPR84 (0.45) | GPR84FFAR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15233306 | 0.83 | ALOX15 (0.42) | ALOX15MEN1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL6525840 | 0.82 | ALOX15 (0.41) | ALOX15MEN1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL1118988 | 0.82 | ALOX15 (0.41) | ALOX15MEN1KMT2ASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | claimed |
| CN-118613264-A | Pharmaceutical composition comprising phthalazinone derivatives for co-administration with anticancer drugs | 伊迪恩斯股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-107299072-B | Engineering bacterium and application thereof | 江南大学 | 2020-11-06 | — | — | CN | disclosed |
| US-20190029941-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | Dermaforce Holdings, LLC | 2019-01-31 | — | — | US | disclosed |
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | PCR TECHNOLOGY HOLDINGS, LC (US) | 2018-11-13 | — | — | US | disclosed |
| CN-107299072-A | Engineering bacterium and application thereof | 江南大学 | 2017-10-27 | — | — | CN | disclosed |
| US-20160287507-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | Dermaforce Holdings, LLC | 2016-10-06 | — | — | US | disclosed |
| EP-3068495-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | US CosmeceuTechs LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073769-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | US COSMECEUTECHS LLC (US) | 2015-05-21 | — | — | WO | disclosed |
| US-8927773-B2 | Process for the direct amination of secondary alcohols with ammonia to give primary amines | EVONIK DEGUSSA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-20130165672-A1 | PROCESS FOR THE DIRECT AMINATION OF SECONDARY ALCOHOLS WITH AMMONIA TO GIVE PRIMARY AMINES | EVONIK DEGUSSA GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | RARA, LRAT, RARG | GPR84 566/4885FFAR1 312/4885ALOX15 120/4885 |
| US-20130165672-A1 | PROCESS FOR THE DIRECT AMINATION OF SECONDARY ALCOHOLS WITH AMMONIA TO GIVE PRIMARY AMINES | ADH1C, ADH5, ADH1A | GPR84 3232/4885FFAR1 640/4885ALOX15 1382/4885 |
| US-20190029941-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | RARA, RARG, RXRA | GPR84 846/4885FFAR1 903/4885ALOX15 576/4885 |
| US-20160287507-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | RARA, RARG, RXRA | GPR84 318/4885FFAR1 221/4885ALOX15 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.